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MicroRNAs (miRNAs) have been demonstrated to play critical roles in many physiological and pathophysiological
processes. The presence of altered miRNA profiles in human body fluids has been reported for a number of
diseases including gynecological malignancies. In this review, we summarized the current progresses of circulating
miRNAs associated with malignancies in gynecology, with an emphasizing on the circulating miRNAs as diagnostic
and prognostic biomarkers in ovarian cancer, endometrial carcinoma and cervical cancer.Introduction
Cancer has long been one of the major causes of death
worldwide. Along with its increasing incidence and mor-
tality, enormous efforts have been made on etiology,
pathophysiology, diagnosis and therapeutics of multiple
malignancies, including gynecological neoplasms. Ovarian
cancer, together with endometrial cancer and cervical car-
cinoma, are the three most common gynecological malig-
nant tumors. They contributed more than 2/3 of new cases
of cancer in female genital system every year. And, ovarian
cancer, ranked the fifths of all female malignancies, causing
14,270 deaths in US per year [1]. It is the highest in gyneco-
logic tumors.
Current diagnostic methods for cancer, especially ma-
lignancies of female reproductive tract, mainly depend
on typical symptoms and screening tests, such as pelvic
examination, transvaginal ultrasound, and tumor bio-
markers. However, many tumors are asymptomatic at
early stage, like ovarian cancer. And on the other side,
examinations and biomarkers are not yet sensitive or
sufficiently specific for tumor detection. Consequently,
finding reliable methods/biomarkers for early diagnosis
of cancer remains a significant clinical challenge.
MicroRNAs (miRNAs), a class of small RNAs approxi-
mately 18–22 nucleotides in length, were initially discov-
ered in 1993. The regulatory function of miRNAs was
proven to be inducing either translation suppression or* Correspondence: dr-hong-clinic@163.com
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unless otherwise stated.degradation of RNA. Investigations have suggested that
miRNAs are related to a lot of physiological processes
[2,3], and their dysregulation can lead to the occurrence
and progression of diseases. Researchers found that
miRNAs might be involved in the pathogenesis of a
variety of human cancers, such as lung cancer [4], pros-
tate cancer [5], colorectal tumor [6] and leukemia [7,8],
as either oncogenes or onco-suppressors.
Emerging evidences of miRNAs in circulation and in
body fluids, such as serum [9], human whole saliva [10],
and urine [11], have initiated a new era of disease research.
Circulatory miRNAs are reported mainly from monocytes,
plasma, and exosomes [9,12], and resistant to degradation
by RNase enzyme thus stable in the blood [13]. A lot of
profiling studies have linked miRNAs to possible bio-
markers for disorders, both diagnostic and prognostic.
Consequently, the potential role of miRNAs in clinical
practice lies in not only the early diagnosis and classifica-
tion of tumors, but also the identification of poorly differen-
tiated malignancies and the prediction of survival and
response to treatment.
For tumors of human female reproductive tract, investi-
gations have revealed the differential expression of miRNAs
in tissue as well as blood/serum samples. These findings
had been further linked to recognition and monitoring of
tumors. Here in this review we highlighted the new pro-
gresses on the role of circulating miRNAs associated with
malignancies in gynecology.
Ovarian cancer and circulating MiRNAs
Ovarian cancer is one of the deadliest gynecologic malig-
nancies worldwide, and epithelial ovarian cancer (EOC)td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Carbohydrate antigen-125 (CA-125), and Human Epididy-
mis Protein 4 (HE4), are the most widely used biomarkers
for EOC diagnosis, of which sensitivity and specificity are
not quite satisfied. About 70% of patients are diagnosed
in advanced clinical stages of the disease due to lack of
effective screening methods [14]. Therefore, finding reliable
biomarkers for the early diagnosis of ovarian cancer re-
mains a crucial topic.
Proven to be stable and conservative in circulation, a var-
iety of miRNAs were revealed differently expressed in ovar-
ian carcinomas and in disease specific conditions. Advances
in applications of miRNAs as diagnostic and prognostic
biomarkers have also caught attentions of scientists.
Taylor et al. isolated circulating tumor-derived exosomes
from sera of patients diagnosed with ovarian serous papil-
lary adenocarcinoma, and for the first time reported
that eight circulating miRNAs were differentially expressed
between ovarian cancer patients and benign controls [13].
This investigation, followed by several profiling studies
[15-19], raised the possibility that miRNAs could potentially
be used as surrogate diagnostic markers for biopsy. Table 1
summarized the differential expression miRNAs in profiling
studies. As revealed recently, expression level of miR-26a in
plasma was reported to be able to distinguish EOC patients
from healthy controls [20]. And interestingly, the results of
Resnick’s investigation showed that serum levels of miR-
NAs were not consistent with serum CA-125 levels, the
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#OC: ovarian cancer, ##EAOC: endometriosis-associated ovarian cancer.92 and 93 were significantly over-expressed in patients with
normal CA-125, highlighting the prospect of circulating
miRNAs as non-invasive biomarkers of cancer detection.
On the basis of expression profiling, researchers fur-
ther tried to analyze the utility of circulating miRNAs in
diagnosing ovarian cancers. Kan et al. [21] reported that
the expressions of miR-200a, miR-200b and 200c were
significantly up-regulated in sera of patients diagnosed
with serous epithelial ovarian cancer (n = 28). They
founded an efficient predictive model with normalized
miR-200b and miR-200c (ROC-AUC = 0.784). Although
the sample size of this study was limited, it lighted up the
chance of using serum miRNAs as promising discriminat-
ing tools of ovarian cancer. In a larger sample analysis (360
epithelial ovarian cancer patients and 200 healthy controls),
Zheng [19] and coworkers found higher miR-205 and lower
let-7f expression in plasma of cases than that of controls.
Furthermore, the levels of miR-205 and let-7f together pro-
vided high diagnostic accuracy for ovarian cancer patients,
especially for stage I disease. The combination of these two
miRNAs, together with CA-125 further improved the ac-
curacy of detection, suggesting a good possibility in improv-
ing the current deficiency of early ovarian cancer diagnosis.
Despite the potential role of circulating miRNAs in
distinguishing ovarian cancers from healthy controls and
benign tumors, the expression levels of some miRNAs
have been revealed to be associated with some clinico-
pathological features of cancer. The concentration of
miR-221 in sera of patients with epithelial ovarian canceran cancer in profiling studies
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Furthermore, the expression level of serum miR-221 was
significantly associated with International Federation of
Gynecology and Obstetrics (FIGO) stage and tumor
grade. And, through multivariate analysis of overall sur-
vival, high serum miR-221 expression was confirmed as
an independent unfavorable prognostic factor in EOC.
Guo et al. [23] found a significant correlation between
miR-92 expression and regional lymph node involve-
ment and clinical stage of the tumor, while there was
no significant association between expression of miR-92
and age. This suggested the possibility of up-regulated
miR-92 levels as a prognostic biomarker. Increased serum
miR-21 expression was also proved to be correlated with
advanced FIGO stage, high tumor grade, and shortened
overall survival [24]. And in Zheng’s study, they raised the
correlation between lower let-7f and poor prognosis in
EOC patients, indicating let-7f may be predictive of ovarian
cancer prognosis [19]. In addition, Shapira et al. [17]
analyzed the follow-up outcome and pre-surgery plasma
miRNA levels of women diagnosed with ovarian cancer.
Significant differences in 5 miRNA expressions were found
in women who had short overall survival (SOS) compared
to women with long overall survival (LOS). And after
correction for multiple testing, level of miR-1290 was
confirmed significantly different between the two groups
(adj.P-value = 0.05, AUC = 0.87), giving a great chance of
serum miRNAs as monitoring and prognostic biomarkers.
Circulating MicroRNA signatures in endometrial
carcinoma
Endometrial carcinomas is one of the most common malig-
nant tumors of the female reproductive tract, and approxi-
mately 80% of endometrial cancers are of endometrioid
histology [25]. Diagnosed mostly in early clinical stages,
again despite a great improvement in endometrial cancer
treatment and diagnosis, advanced stages of the disease
are still difficult to manage with the 5-year survival
rate of ~10–29% [26]. Highly sensitive and specific mo-
lecular prognostic biomarkers are required to better
predict the outcome of endometrioid endometrial
cancer (EEC). Recent study identified that miR-194 has
potential to serve as prognostic biomarker for endo-
metrial cancer [27]. However, circulating miRNAs
involved in ECC were not analyzed as much as in
ovarian cancers.
Tan et al. tried to use the serum level of miR-155
to differentiated EEC from healthy controls, and other
histological types of endometrial carcinomas [28]. They
found that the increase of miR-155 expression was asso-
ciated with cancer stage, and lymph node metastasis
(LNM). The potential of circulating miRNAs serving as
diagnostic and prognostic markers was then confirmed
by other researchers. Torres and coworkers [29] foundthat the expression of miR-99a, miR-100 and miR-199b
was up-regulated in plasma of EEC patients, and a com-
bination of miR-99a and miR-199b was more accurate in
distinguishing EEC disease when compared with single
miRNAs. Another genome-wide serum miRNA expres-
sion profile identified a combination of four serum
miRNAs (miR-222, miR-223, miR-186 and miR-204) as a
fingerprint for EEC detection. The ROC-AUC was 0.927,
which was markedly higher than that of CA-125 (0.673),
showing a better accuracy.
Other investigations of miRNA profiling in EEC have
tried to make associations between circulating miRNAs
and the clinicopathological characteristics [30,31]. Ex-
pression of a number of miRNAs was showed to have
links to signatures like FIGO stage, grade, relapse and
nodal metastases, while the relations were mostly linked
to miRNAs expression in tissue samples.
Circulating MiRNA studies in cervical cancer
Cervical cancer is a primary cancer of the uterine cervix in
female whose development is a multistep process initiated
by persistent infection with high-risk human papillomavi-
rus. Although the mortality of cervical cancer was de-
creasing in area with advanced healthcare and prevention
system, the incidence is still high worldwide. Thanks to
the effective screening methods for cervical cancer, studies
focused on extracellular miRNAs and cervical cancer were
limited. In our recent work, we demonstrated that the
circulating miRNAs, miR-646, miR-141* and miR-542-3p
were differentially expressed in the serum of cervical
squamous cell carcinoma (SCC) patients before and
after surgery, thus could potentially serve as non-
invasive biomarkers and post-therapeutic monitors for
cervical SCC [32].
Researchers investigated the expression of miR-218 in
the sera from cervical cancer patients and its relation-
ships with clinicopathological characteristics [33]. MiR-
218 was reduced significantly in the sera of cervical can-
cer patients. Moreover, decreased miR-218 was reported
to be associated with later stages, cervical adenocarcin-
oma, and lymphatic node metastasis. And in another re-
search, Zhao et al. [34] found that the expression levels
of miR-20a and miR-203 were both significantly higher
in cervical cancer patients compared with healthy controls.
Patients with LNM tended to have overexpression of miR-
20a, but down-regulation of miR-203. The authors took
further study to analyze the efficiency of using miR-20a to
differentiate LNM (+) patients from LNM (−) patients. The
value of the area under the receiver-operating curve (AUC)
was 0.734 ± 0.058, the sensitivity and specificity of serum
miR-20a were 75% and 72.5%, respectively, and the cut-off
point was 3.0. These results suggested that the circulating
miR-20a may be a potential biomarker for detecting the
lymph node status of cervical cancer patients.
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features of cervical SCC, more than one research fo-
cused on the detection of LNM. Chen et al. [35] exam-
ined the expression levels of miRNAs that dysregulated
between LNM (+) and LNM (−) SCC samples, both in
tissue samples and in sera of patients and healthy con-
trols. They identified 6 serum miRNAs that can predict
LNM in cervical SCC patients: miR-1246, miR-20a, miR-
2392, miR-3147, miR-3162-5p and miR-4484. Furthermore,
they analyzed the prediction value of LNM using compre-
hensive set of these serum microRNAs. The ROC-AUC
reached to 0.932. As shown in their results, the predictive
value of the serum miRNAs was inferior to that in tissue,
but far superior to serum SCC antigen (SCC-Ag) analysis,
suggesting that serum miRNAs are potential novel predic-
tors of LNM with clinical value in early-stage cervical SCC.
Future perspectives
Circulating miRNAs have been proposed as diagnostic
and prognostic biomarkers for gynecological malignan-
cies, including ovarian cancer, endometrial carcinoma
and cervical cancer. There exists a high level of incon-
sistency across present studies as many results have
been reported only within one or a few times so far.
And there will be a long way to go before we can really
use these findings in clinical work. In addition, the
production and metabolic pathways of circulating
miRNAs, as well as their function remain unclear to
date and need further investigation.
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